The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer
Open accessAbstract
Intrinsic and acquired resistance to anti-EGFR antibody therapy, frequently mediated by a mutant or amplified KRAS oncogene, is a significant challenge in the treatment of colorectal cancer (CRC). However, the mechanism of KRAS-mediated therapeutic resistance is not well understood. In this study, we demonstrate that clinically used anti-EGFR antibodies, including cetuximab and panitumumab, induce killing of sensitive CRC cells through p73-dependent transcriptional activation of the pro-apoptotic Bcl-2 family protein PUMA. PUMA induction and p73 activation are abrogated in CRC cells with acquired resistance to anti-EGFR antibodies due to KRAS alterations. Inhibition of aurora kinases preferentially kills mutant KRAS CRC cells and overcomes KRAS-mediated resistance to anti-EGFR antibodies in vitro and in vivo by restoring PUMA induction. Our results suggest that PUMA plays a critical role in meditating the sensitivity of CRC cells to anti-EGFR antibodies, and that restoration of PUMA-mediated apoptosis is a promising approach to improve the efficacy of EGFR-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibition of AURKA could sensitize KRAS-mutant CRC and NSCLC to EGFR-targeted therapy [135, 136].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“CRCs with mutant or amplified KRAS are invariably insensitive to anti-EGFR antibody therapy [6, 22, 23].”
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“A variety of approaches have been explored to target mutant KRAS, such as directly inhibiting KRAS [13], and targeting KRAS downstream effector pathways [4, 14].”
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 8×
“Consistent with previous studies [11, 14], the cetuximab-resistant DiFi cells had markedly elevated KRAS expression due to KRAS genomic amplification, and expressed a much lower level of total EGFR (Fig.”
InfluentialSelf-citationRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 2×
“KRAS encodes a small GTPase that mediates signals from growth factor receptors to downstream PI3K/AKT and MEK/ERK effector pathways [8].”
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“It has been shown that continuous exposure of sensitive CRC cells to anti-EGFR antibodies enriches a small fraction of cells with a KRAS mutation or genomic amplification, which underlies acquired resistance to anti-EGFR antibodies [11, 12].”
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467 · cited 1×
“KRAS mutations, mostly at codons 12, 13, and 61, lock KRAS into a constitutively active GTP-bound form, resulting in hyperactive PI3K/AKT and RAF/MEK/ERK signaling [9], as well as resistance to anti-EGFR antibody therapy [10].”
Cited by
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 132
Self-citationMcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer
Song, X., Shen, L., Tong, J., Kuang, C., Zeng, S., Schoen, R. E., Yu, J., Pei, H., & Zhang, L. (2020) · Theranostics · doi:10.7150/thno.45363 · Cited by 77
Self-citationTargeting Myc-driven stress addiction in colorectal cancer
Saeed, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100963 · Cited by 61
Self-citationMicroRNA‐155‐3p promotes glioma progression and temozolomide resistance by targeting Six1
Chen, G., Chen, Z., & Zhao, H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15192 · Cited by 50
Ji, Y., Yang, S., Tian, H. W., Zhang, Y., & Zhao, H. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03154-w · Cited by 44
Retracted
Metadata
- Authors
- Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L.
- Affiliations
- University of Pittsburgh (US)
- Memorial Sloan Kettering Cancer Center (US)
- Candiolo Cancer Institute (IT)
- Corresponding author
- Zhang, Lin
- Venue
- Oncogene
- Published
- 2018-05-14
- Volume
- 37
- Issue
- 33
- Pages
- 4599-4610
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC6195818
- OpenAlex
- W2801274882
- Cited by
- 33
- References
- 45
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 5 · 2021: 3 · 2020: 13 · 2019: 5 · 2018: 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-05-16)
- Open access
- green
- europepmc.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Cotswold Foundation
- National Institutes of Health
- National Cancer Institute (R01CA106348, R01CA172136, R01CA215481, R01CA217141, R01CA203028, P30CA008748, P30CA047904)
- National Institute of Allergy and Infectious Diseases (U19AI068021)
- National Institute of Diabetes and Digestive and Kidney Diseases (U24DK085532, U01DK085570, U01DK085532)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- PUMA, KRAS mutation, anti-EGFR antibody resistance, cetuximab, panitumumab, colorectal cancer, p73, Aurora kinase inhibition, apoptosis, anti-EGFR therapy, acquired drug resistance
- MeSH terms
- Cetuximab, Panitumumab, Animals, Antibodies, Monoclonal, Female, Humans, Mice, Nude, Proto-Oncogene Proteins, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Apoptosis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, HCT116 Cells, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. https://app.cochat.ai/papers/10.1038/s41388-018-0289-x
- The paper
- Knickelbein, K., Tong, J., Chen, D., Wang, Y.-J., Misale, S., Bardelli, A., Yu, J., & Zhang, L. (2018). Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. Oncogene. https://doi.org/10.1038/s41388-018-0289-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.